VALIRX PLC LS-001
Research VALIRX PLC LS-001 (EAJF) on Bullrun: market cap EUR 660.15K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEAJF
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 660.15K
- Financial periodFY2025
- RevenueGBP 31.37K
- Revenue growth-37.0%
- Net income-GBP 2.23M
- Free cash flow-GBP 1.52M
- Gross margin-19.9%
Valuation Snapshot
latest market cap is EUR 660.15K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 31.37K | -GBP 2.23M | -GBP 1.52M | -19.9% | -0.01 | GBP 791.61K | GBP 1.40K | GBP 2.86M |
| FY2024 | GBP 49.78K | -GBP 1.92M | -GBP 1.62M | 100.0% | -0.01 | GBP 1.56M | GBP 11.86K | GBP 4.32M |
| FY2023 | GBP 9.60K | -GBP 2.04M | -GBP 2.08M | 85.0% | -0.02 | GBP 174.68K | GBP 22.07K | GBP 3.22M |
| FY2022 | GBP 0 | -GBP 2.37M | -GBP 1.71M | n/a | -0.03 | GBP 1.14M | GBP 37.71K | GBP 4.05M |
| FY2021 | GBP 0 | -GBP 1.52M | -GBP 1.26M | n/a | -0.02 | GBP 593.67K | GBP 58.72K | GBP 3.60M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | EUR 660.15K | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About VALIRX PLC LS-001
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VALIRX PLC LS-001's market cap?
VALIRX PLC LS-001's market capitalization is EUR 660.15K.
What does VALIRX PLC LS-001 do?
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis.